Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
|
CN |
Cardio Diagnostics Holdings Inc
Non-Reccuring Items
Cardio Diagnostics Holdings Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Non-Reccuring Items
-$344m
|
CAGR 3-Years
34%
|
CAGR 5-Years
54%
|
CAGR 10-Years
16%
|
|
|
Schlumberger NV
NYSE:SLB
|
Non-Reccuring Items
-$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
38%
|
CAGR 10-Years
8%
|
|
|
Halliburton Co
NYSE:HAL
|
Non-Reccuring Items
-$831m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
27%
|
CAGR 10-Years
10%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Non-Reccuring Items
-$42.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cardio Diagnostics Holdings Inc
Glance View
Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.
